...
首页> 外文期刊>Journal of Neurology >Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin
【24h】

Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin

机译:脑源性脑缺血后口服抗凝治疗期间的止血基因变异,ABO血型和出血风险

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Oral anticoagulant treatment for secondary prevention after cerebral ischaemia of presumed arterial origin is associated with a higher bleeding rate than cardioembolic stroke. This discrepancy is only partly explained by known bleeding risk factors. Haemostatic genetic variants and AB0 blood group may be involved.
机译:假定的动脉源性脑缺血后,口服抗凝剂二级预防与心脏栓塞性中风的出血率较高相关。这种差异只能由已知的出血风险因素部分解释。可能涉及止血遗传变异和AB0血型。

著录项

  • 来源
    《Journal of Neurology》 |2007年第12期|1660-1665|共6页
  • 作者单位

    Dept. of Neurology Rudolf Magnus Institute of Neuroscience University Medical Center Utrecht The Netherlands;

    Dept. of Clinical Epidemiology and Haematology Leiden University Medical Center The Netherlands;

    Dept. of Neurology Rudolf Magnus Institute of Neuroscience University Medical Center Utrecht The Netherlands;

    Center for Experimental and Molecular Medicine Academic Medical Center Amsterdam The Netherlands;

    Dept. of Neurology Rudolf Magnus Institute of Neuroscience University Medical Center Utrecht The Netherlands;

    Dept. of Neurology Rudolf Magnus Institute of Neuroscience University Medical Center Utrecht The Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    polymorphism; ischaemic stroke; haemostasis; anticoagulant; bleeding risk;

    机译:多态性;缺血性中风;止血;抗凝剂;出血风险;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号